Drug Company "PTSD will significantly enhance partnering potential"

So, why are so many doing stuff to "treat" PTSD while it has gotten worse? Here's your answer. FOLLOW THE MONEY!
This is a press release!

Post Traumatic Stress Disorder Identified as Major New Market Opportunity for BNC210
PR Newswire
ADELAIDE, Australia
Dec. 8, 2015

It is estimated that approximately 8 million Americans, or 3.5% of the US population, suffer PTSD at any given time. Similarly, an estimated 1 million Australians experience PTSD in any year[1], and 12% of Australians will experience PTSD during their lifetime[1].

A substantial additional market opportunity for BNC210 has been identified and will be developed via a Phase 2 trial funded by a US$12m placement Data supporting the use of BNC210 for PTSD will significantly enhance partnering potential and the value created for BNO shareholders The placement of US$12m, following the Merck and Co. Inc, (MSD) investment, reflects increasing interest from US investors as BNO builds greater visibility in the US

Australian drug development company Bionomics Limited (ASX:BNO, OTCQX:BNOEF) will launch a key Phase 2 trial of its novel anxiety drug BNC210 as a treatment for post-traumatic stress disorder (PTSD), following a US$12 million private placement to US institutional investors.

The new trial is expected to begin in the first half of 2016, with patients to be recruited at several trial sites in Australia and New Zealand. All patients enrolled will have experienced severe trauma, including war, natural disasters or have been involved in serious accidents.

The program will be funded with a US$12 million Private Placement to four US institutional investors.

Under the placement 40,207,472 shares will be issued at A$0.408 per share with attaching 40,207,472 warrants to purchase shares at A$0.5938 per share (the same price as the MSD investment), of which 16,082,988 warrants will be subject to shareholder approval at a shareholder meeting to be held early in 2016. Roth Capital Partners acted as the sole US Placement Agent in the transaction.

The Board recommends that shareholders vote to approve the issue of the warrants. The Board further advises that individual Board members will vote their shareholdings in favour of the issue of the warrants.

Bionomics CEO and Managing Director Dr Deborah Rathjen said all existing data indicated that BNC210, which is currently in trial to treat Generalised Anxiety Disorder, could be an effective therapy for PTSD patients.
read more here

Tenex PTSD Drug Is No More Effective Than Placebo

Common PTSD Drug Is No More Effective Than Placebo

Guanfacine, a medication commonly prescribed to alleviate symptoms of post-traumatic stress disorder, is no more effective than a placebo, according to a study led by researchers at the San Francisco VA Medical Center.

"There was no benefit at all, and there were several adverse side effects," says lead author Thomas Neylan, MD, medical director of the PTSD treatment program at SFVAMC. "People with symptoms of PTSD should probably stay away from this drug and others of its type.
go here for more
http://www.all-healthtalk.com/common-ptsd-drug-is-no-more-effective-than-placebo.html

But calling it a placebo makes people think it does no harm.

BODY AS A WHOLE asthenia, chest pain, edema, malaise, tremor
CARDIOVASCULAR bradycardia, palpitations, syncope, tachycardia
CENTRAL NERVOUS SYSTEM paresthesias, vertigo
EYE DISORDERS blurred vision
GASTROINTESTINAL SYSTEM abdominal pain, constipation, diarrhea, dyspepsia
LIVER AND BILIARY SYSTEM abnormal liver function tests
MUSCULO-SKELETAL SYSTEM arthralgia, leg cramps, leg pain, myalgia
PSYCHIATRIC agitation, anxiety, confusion, depression, insomnia, nervousnessREPRODUCTIVE SYSTEM, MALE impotence
RESPIRATORY SYSTEM dyspnea
SKIN AND APPENDAGES alopecia, dermatitis, exfoliative dermatitis, pruritus rash
SPECIAL SENSES alterations in taste
URINARY SYSTEM nocturia, urinary frequency


http://www.drugs.com/pro/guanfacine.html

GENERIC NAME: GUANFACINE - ORAL (GWAN-fuh-seen)

BRAND NAME(S): Tenex
SIDE EFFECTS: Dizziness, drowsiness, headache, constipation, gas pains, diarrhea, loss of appetite, fatigue, and nasal congestion may occur. If these symptoms persist or worsen, notify your doctor. Inform your doctor if you develop: chest pain, shortness of breath, skin rash, swelling of the hands or feet, blurred vision, yellowing of the eyes or skin. Inform your doctor if you experience any of these symptoms: mental/mood changes, tingling of the hands or feet, dry mouth, impotence, decreased sexual desire, vision changes, taste changes, ringing in the ears, leg cramps. If you notice other effects not listed above, contact your doctor or pharmacist.

PRECAUTIONS: Tell your doctor your medical history, especially of: heart or circulatory problems, kidney or liver disease, any allergies. Limit your intake of alcoholic beverages while taking this medication. Alcohol can lead to excessive drowsiness, dizziness or fainting.
Also, avoid hot showers, saunas and prolonged exercise since excessive heat can intensify dizziness.
Caution is advised when performing tasks requiring alertness (e.g., driving), since this drug may cause drowsiness.
To minimize dizziness and lightheadedness when rising from a seated or lying position, get up slowly Before having surgery, including dental surgery, tell the doctor or dentist in charge about your blood pressure medications.
Caution is advised when using this drug in the elderly because they may be more sensitive to the side effects of the drug. This medication should be used only when clearly needed during pregnancy. Discuss the risks and benefits with your doctor. It is not known if guanfacine passes into breast milk. Consult your doctor before breast-feeding.
http://www.medicinenet.com/guanfacine-oral/article.htm